ライフサイエンスコーパス: T-cell response

1 es the timing, magnitude, and quality of the T cell response.

2 is infection contribute significantly to its T cell response.

3 tor T cell survival into an efficient CD4(+) T cell response.

4 canonical antigenic epitopes targeted by the T cell response.

5 lenge and dominated in the subsequent CD8(+) T cell response.

6 ecific gamma interferon-dominated Th1-biased T cell response.

7 ust control development of the drug-specific T cell response.

8 berghei infection is dominated by a Vbeta8.1 T cell response.

9 The immunized mice also developed a robust T cell response.

10 ibution of plasminogen was downstream of the T-cell response.

11 tion, and induction of a Bet v 1-independent T-cell response.

12 n and the subsequent development of effector T cell responses.

13 associated with reduced ex vivo HIV-specific T cell responses.

14 of alloantigen that drives CD8(+) cytotoxic T cell responses.

15 9 for anticancer therapy enhancing antitumor T cell responses.

16 cteristics of tolDCs and subsequent effector T cell responses.

17 ice correlated with impaired effector CD8(+) T cell responses.

18 f IRF-1 prior to induction of adaptive B and T cell responses.

19 ation involving IL-36R/MyD88-dependent IL-17 T cell responses.

20 ry cells can actively control autoaggressive T cell responses.

21 activate them to prime tumor-specific CD8(+) T cell responses.

22 tive nature of these potentially destructive T cell responses.

23 cytokines that can induce antitumour CD8(+) T cell responses.

24 unomodulatory receptors to promote cytotoxic T cell responses.

25 mouse model for investigating ZIKV-specific T cell responses.

26 infection correlates with host CD4+ and CD8+ T cell responses.

27 cular brake controlling the magnitude of CD8 T cell responses.

28 e checkpoint role in inhibiting inflammatory T cell responses.

29 ration and reprogramming during inflammatory T cell responses.

30 their elimination restored antiviral CD8(+) T cell responses.

31 ame mechanism of controlling proinflammatory T cell responses.

32 ot the MVAgp140 boost, increased peak CD4(+) T cell responses.

33 s high permselectivity and strong allogeneic T cell responses.

34 iral vectors and is known to generate potent T cell responses.

35 itizing cytokines and promotion of antitumor T cell responses.

36 t aim for effective and balanced humoral and T cell responses.

37 tion in absence of detectable PvCSP-specific T cell responses.

38 re essential for the appropriate analysis of T cell responses.

39 nificant role in regulating antigen-specific T-cell responses.

40 en binding, virus neutralizing antibody, and T-cell responses.

41 tabolism and function to limit DC-stimulated T-cell responses.

42 ll death-1 (PD-1) is a negative regulator of T-cell responses.

43 kade (ICB) therapies can unleash anti-tumour T-cell responses.

44 immunoregulatory checkpoints that attenuate T-cell responses.

45 s in the control of adaptive and innate-like T-cell responses.

46 ct on the magnitude or quality of intragraft T-cell responses.

47 of immunization affected the level of CD4(+) T-cell responses.

48 f LPS-stimulated DCs and inhibits DC-induced T-cell responses.

49 ttributed to nonfunctional intrahepatic CD8+ T-cell responses.

50 ociated with acute inflammatory or cytotoxic T-cell responses.

51 season or vaccination to assess antibody and T-cell responses.

52 ssociated with effective Gag-specific CD8(+) T-cell responses.

53 lpha-(1,3)-glucan-mediated DC activation and T-cell responses.

54 strated that it safely induced serologic and T-cell responses.

55 t alterations in basophil reactivity but not T-cell responses.

56 inhibited, altering DC outputs and enhancing T-cell responses.

57 are no longer able to stimulate adequate CD8 T cells responses.

58 The definition of CD4(+) T cell responses after live vaccination is important bec

59 Effective T cell responses against invading pathogens require the

60 Peripheral tumor-specific T cell responses against main SCC-derived antigens using

61 s with asymptomatic infection have exhibited T cell responses against specific HSV-2 antigens not obs

62 er IgG and robust gamma interferon-secreting T cell responses against the proteins.

63 The immune system can mount T cell responses against tumors; however, the antigen sp

64 nhibition of human T cells show that maximal T-cell responses against autoantigen or repeated tetanus

65 f CD4 TEMRA cells and provides insights into T-cell responses against DENV and other viral pathogens.

66 We examined T-cell responses against gluten by generating T-cell lin

67 otherapy is highly effective at reactivating T-cell responses against melanoma, which is postulated t

68 It precludes specific T-cell responses against strong antigens and we found ve

69 CD8(+) T-cell responses against the AAV capsid protein can, how

70 and pigs, where specific CD8(+) T and CD4(+) T-cell responses against the GOI-encoded antigen were ob

71 t residual Tregs were able to control CD8(+) T-cell responses against the tumor.

72 Fibroblasts possess the capacity to suppress T cell responses, although the molecular mechanisms of t

73 on induced a protective VACV-specific CD8(+) T cell response and protected against a lethal VACV chal

74 s during vaccination impaired protective CD8 T cell responses and ablated sterile protection.

75 asy-to-implement research tool for measuring T cell responses and cellular metabolic changes in vitro

76 ch should greatly accelerate the analysis of T cell responses and expedite the identification of spec

77 cDC were superior in stimulating allogeneic T cell responses and in cross-presenting viral antigens

78 serovar Typhimurium (S Typhimurium) inhibits T cell responses and mediates virulence.

79 ward a higher magnitude of CD4(+) and CD8(+) T cell responses and neutralization of some HIV-1 strain

80 ity associated with hyperactive conventional T cell responses and poor Treg-mediated suppression.

81 PRMT5 blockade efficiently suppressed recall T cell responses and reduced inflammation in delayed-typ

82 ll death-1 (PD-1)-targeted therapies enhance T cell responses and show efficacy in multiple cancers,

83 ase was associated with the induction of CD4 T cell responses and the epitope preferentially binds MH

84 pproaches to reverse these programs improved T cell responses and tumor control during ICB.

85 shown to confer a strong IAV-specific CD8(+) T-cell response and a strong cross-strain as well as cro

86 anti- Pp IgG antibody nor in vitro anti- Pp T-cell response and resultant production of RANKL was af

87 ssociated with decreased inflammatory CD4(+) T-cell responses and a correlation between B7-H4-express

88 th and magnitude of the total virus-specific T-cell responses and directly with plasma levels of mole

89 he DC microenvironment to control DC-induced T-cell responses and indicate that glucose is an importa

90 ciation of TOLLIP variation with BCG-induced T-cell responses and susceptibility to latent tuberculos

91 has a multifunctional role for enhancing CAR T-cell responses and that this combination therapy has h

92 that share cross-reactivity in antibody and T cell responses, and co-circulate in increasing numbers

93 tablished EsxA secretion, host specific EsxA T-cell responses, and increased strain virulence.

94 ting CD8(+) cells, low virus-specific CD4(+) T-cell responses, and low Env antibody titers.

95 gainst GVHD by modulating alloreactive donor T-cell responses, and that CXCR3 signaling may be an imp

96 of 36) developed a robust immunodominant CD8 T cell response apparently cross-reactive between a newl

97 The factors that drive the alloreactive T cell response are not completely understood.

98 spectratyping revealed that SMX-NO-specific T cell responses are controlled by public TCRs present i

99 Strong and long-lasting antigen-specific T cell responses are critical for therapy of these disea

100 As all memory T cell responses are encoded in the common format of som

101 While early effector T cell responses are required for limiting parasitemia,

102 is that the attributes of protective CD4(+) T cell responses are still elusive for human TB.

103 Tumor-specific T cell responses are strongly impaired in CNI-treated pa

104 CD8(+) gamma interferon (IFN-gamma)-positive T-cell responses are essential for reducing parasite bur

105 ections have provided the most insight, with T cell responses as well as detailed antibody responses

106 MDSCs were suppressive of autologous T-cell responses as evidenced by reduced T-cell prolifer

107 t improved the quality of Ag-specific CD8(+) T cell responses associated with a decrease in inhibitor

108 loads in the stomach by modulating effector T cell responses at the gastric mucosa.

109 ed more likely to mount a transgene-specific T cell response because of a lack of immune tolerance to

110 strate that initiation of the Vgamma9Vdelta2 T cell response begins with sensing of pAg via the intra

111 te source and suppressed diabetogenic CD8(+) T-cell responses both directly and through an intermedia

112 responses, whereas 11 made feeble gammadelta T cell responses but stronger NK cell responses.

113 B is capable of mounting an antigen specific T cell response by efficiently stimulating antigen cross

114 SOCS1 in dendritic cells (DCs) would improve T cell responses by accentuating IFN-gamma-directed immu

115 Purpose Ipilimumab increases antitumor T-cell responses by binding to cytotoxic T-lymphocyte an

116 cy of vaccines designed to induce protective T cell responses can be positively modulated with chemic

117 While effective CD8 T-cell responses can control viral replication in conjun

118 atent virus that elicits different cytotoxic T cell responses characterized as acute resolving or inf

119 correlate of protection from disease, robust T cell responses could enhance ZIKV vaccine efficacy.

120 de and functionality of ex vivo HCV-specific T-cell responses did not increase following RG-101 injec

121 Functional HCV-specific interferon-gamma T-cell responses did not significantly change in patient

122 in (HA) which potentially enhance regulatory T cell response due to conservation with the human genom

123 mportant for boosting optimal primary CD4(+) T cell response during NS4B-P38G vaccination.

124 pecific inhibitor of mTOR, on B cell and CD4 T cell responses during acute infection with lymphocytic

125 by differentially regulating B cell and CD4 T cell responses during acute viral infection and that r

126 l role for CD103(+) cDCs in antigen-specific T cell responses during subclinical viral myocarditis.

127 key transcriptional determinant controlling T cell responses during transplantation.

128 Here we study the CD4 T cell responses elicited by a tetravalent live attenuat

129 ycoprotein (GP) and examined GP-specific CD4 T cell responses elicited by Ad5 vectors and compared th

130 We find that memory T cell responses elicited by prior infection with DENV o

131 Our data show that memory T cell responses elicited by prior infection with DENV r

132 GAP5040-48-specific CD8(+) T cell responses emerged from a very large pool of naive

133 T-cell responses, epitope mapping and cross-reactivity t

134 Naive CD4 T cell responses, especially their ability to help B cel

135 ry receptors, an improved Ag-specific CD8(+) T cell response exhibited by the individual production o

136 As are produced in the absence of identified T cell responses for each citrullinated protein.

137 Both T-cell response frequency (17/26 donors) and strength we

138 E) and the change in HIV-1 Gag-specific CD8+ T cell responses from baseline to day 28 after infusion.

139 bly with traditional methods for determining T cell responses (i.e., [(3)H]thymidine incorporation an

140 may be further impacted by increased CD4(+) T cell responses.IMPORTANCE Prior immune correlate analy

141 A class I molecules restrict the anti-gluten T cell response in CD patients.

142 nerally well controlled by the HCMV-specific T cell response in healthy people.

143 it to investigate heterogeneity in the CD8+ T cell response in humans and mice, and show that it is

144 stricted epitope to which there was a CD8(+) T cell response in mice immunized with our modified dend

145 f antiviral cytokines and an impaired CD4(+) T cell response in peripheral organs.

146 lucidate the kinetics of the effector CD8(+) T cell response in the liver following Plasmodium berghe

147 The magnitude of the K(d)M282-90 CD8(+) T cell response in TLR agonist-treated neonates could be

148 We evaluated the CD8(+) T cell response in ZIKV-infected LysMCre(+)IFNAR(fl/fl)

149 ion to the viral load of HIV-specific CD4(+) T cell responses in a cohort of untreated HIV clade C-in

150 accination induced strong mE6 and mE7 CD8(+) T cell responses in all mice, although they were signifi

151 ding the contribution of HIV-specific CD4(+) T cell responses in clade C infection is particularly im

152 elucidate the global landscape of antitumor T cell responses in complete regression of human papillo

153 were successful in the induction of NAbs and T cell responses in guinea pigs.

154 y analyse the HDM-derived protein targets of T cell responses in HDM-allergic individuals, and invest

155 spot assay to interrogate CD8(+) and CD4(+) T cell responses in healthy volunteers infected with rDE

156 more effective in reducing graft associated T cell responses in liver-Tx than in BM-Tx.

157 tetramers in evaluating HIV-specific CD4(+) T cell responses in natural infections.IMPORTANCE Increa

158 27 and IL-37 in regulating CD4(+) and CD8(+) T cell responses in S. stercoralis infection.

159 ressor cells (MDSCs) are major regulators of T cell responses in several pathological conditions.

160 Meromycolate fine structure influences T cell responses in TB-exposed individuals, and meromyco

161 lloimmune and single antigen-specific memory T cell responses in the absence of immunosuppression or

162 novel role of IL-22 in controlling antiviral T cell responses in the non-lymphoid and lymphoid organs

163 Importantly, CD4(+) T cell responses in vaccinees were similar in magnitude

164 they exerted a potent suppression on CD8(+) T cell responses in vitro.

165 tate can be used to dynamically assess human T cell responses in vitro.

166 s that induce strong peptide-specific CD8(+) T cell responses in vivo by incorporating an NKT cell-ac

167 ired MHC-class I:peptide complexes stimulate T cell responses in vivo, further emphasizing the need t

168 x vivo and defective cross-priming of CD8(+) T cell responses in vivo.

169 We studied the long-term cross-reactive T-cell response in 14 trivalent LAIV-vaccinated children

170 Although the effector T-cell response in patients with celiac disease has been

171 -producing T cells and might thus impact the T-cell responses in asthma.

172 ole of human cytomegalovirus (HCMV)-specific T-cell responses in breast milk of HCMV-seropositive mot

173 LAIV boosts durable, cross-reactive T-cell responses in children and may have a clinically p

174 termine if these inhibitory pathways prevent T-cell responses in HCCs and to find ways to restore the

175 Functional analysis of T-cell responses in HIV-infected individuals has indicat

176 ost effective agents in controlling effector T-cell responses in humans.

177 uency of cytomegalovirus (CMV)-pp65-specific T-cell responses in peripheral blood mononuclear cells (

178 Interestingly, PfSPZ-specific T-cell responses in the blood peaked after the first imm

179 ransformative in promotion of anti-tumor CD8 T-cell responses in the treatment of certain malignancie

180 ay provide new ways to suppress pathological T-cell responses in transplantation or autoimmunity.

181 escribe the appearance of transgene-specific T-cell responses in two subjects that were part of the p

182 s critically required for antigen-stimulated T-cell responses in vitro and in vivo.

183 of infection, but TNF-alpha-specific CD8(+) T-cell responses increased during the chronic phase of i

184 effective method to determine the quality of T cell responses induced by, for instance, T cell vaccin

185 The Chlamydia-specific CD4 T cell response is characterized by the production of IF

186 he unique impact of TLR agonists on neonatal T cell responses is important to consider for RSV vaccin

187 bacterial superantigens trigger a polyclonal T -cell response leading to a potentially catastrophic "

188 rains may differentially modulate the CD4(+) T-cell responses, leading to the generation of Th17 cell

189 nate lymphoid cells (ILCs) regulate adaptive T cell responses led us to examine the regulatory potent

190 In light of dampened CD8(+) T-cell responses, liver disease often manifests systemic

191 T cell response magnitudes increase with increasing anti

192 02 induced robust CD8(+) and moderate CD4(+) T-cell responses, mainly to Ag85B in both vaccine groups

193 We assessed T-cell response markers as correlates of risk in the HIV

194 Detailed knowledge of the T cell response may further contribute to the identifica

195 The HCMV-specific T-cell response may have a role in the prevention of vir

196 elop particularly efficient antiviral CD4(+) T cell responses mediated by shared high-affinity TCRs.

197 antigen presentation are driving the robust T cell response observed during an M. tuberculosis infec

198 mouse model for evaluating anti-ZIKV CD8(+) T cell responses of human relevance.

199 In this study, we describe the CD8 T cell responses of human subjects vaccinated with two f

200 ols intestinal T cell homeostasis and alters T cell responses of mice in different animal facilities.

201 One sero (-) patient developed CMV-T cell responses post-CMV viremia.

202 , we hypothesize that class I restricted CD8 T-cell responses promote development of brain atrophy.

203 Vaccination approaches eliciting strong CD4 T cell responses provide only weak protection from tuber

204 an effector and central memory CD4+ and CD8+ T-cell responses reactive to peptides corresponding to b

205 l decidua, the functional properties of this T cell response remain poorly defined.

206 esponses in preclinical models, particularly T cell responses, remain sparse.

207 In contrast, the antitumoral T-cell response remained largely unchanged.

208 e array, and functional ability to stimulate T cell responses, requires autocrine C3a receptor and C5

209 th cytomegalovirus (CMV) can elicit a CD8(+) T cell response restricted by the human MHC-Ib molecule

210 and similar HIV-1-specific CD4(+) and CD8(+) T cell responses, similar levels of binding IgG antibodi

211 Furthermore, CD4(+) and CD8(+) T cell responses specific to multiple Env epitopes were

212 Here we show blood central memory CD4 T-cell responses specific to Mtb dormancy related (DosR)

213 between the frequency of HIV-specific CD4(+) T cell responses targeting an immunodominant DRB1*11-Gag

214 During CD8(+) T cell responses, Tcf1 long isoforms were dispensable fo

215 e than the other groups, and had even bigger T-cell responses than the older group with a significant

216 sequences from one to three and related the T cell responses that recognize the immunodominant Tax p

217 otective vaccine elicited unconventional CD8 T cell responses that were entirely restricted by MHC II

218 the mice to make adaptive CD4(+) and CD8(+) T cell responses that were necessary to clear the virus

219 oost vaccine strategy induced a Gag-specific T-cell response that was dominated by polyfunctional CD4

220 ne system, together with delivery of optimal T-cell responses that can eliminate the reservoir and se

221 epitope vaccination generated broad-spectrum T-cell responses that potently inhibited tumour growth.

222 exerted a potent immunosuppressive effect on T-cell responses that was mediated by nitric oxide-depen

223 educed in the blood compared with intestine; T-cell responses that we detected had an increased frequ

224 s) promote either tolerogenic or immunogenic T cell responses, the latter upon sensing microbes.

225 ost studies have focused on the induction of T cell responses, the mechanisms by which targeting impr

226 c cells (DCs) are vital for the induction of T-cell responses, the DC subpopulations that induce Th2

227 Consistent with the magnitude of acute T-cell responses, the patient ultimately developed long-

228 s studies have characterized Ad5-induced CD8 T cell responses, there is a relative lack of detailed s

229 ted fibrinogen peptides, in the absence of a T cell response to fibrinogen.

230 Thus, the potency of the T cell response to histoincompatible tissue is likely du

231 The robustness of the T cell response to histoincompatible tissue is not under

232 cids in length can accurately identify a CD4 T cell response to ovalbumin against a background respon

233 The HCMV-specific CD4(+) T cell response to pp65, IE1, IE2, and gB was predominan

234 in humans is appropriate as a model for the T cell response to primary DENV2 infection.

235 S. aureus cell wall downregulates the human T cell response to superantigens through a TLR2-dependen

236 c(+) cells, we observed a decrease in CD8(+) T cell response to the L. monocytogenes vaccine.

237 ramatically decreased the size of the CD8(+) T cell response to two immunodominant epitopes.

238 lts show that type I IFN can suppress CD8(+) T cell responses to cross-presented Ag by depleting cros

239 tation in DCs is required to initiate CD8(+) T cell responses to dead cells and to induce effective a

240 The identification of CD4(+) T cell responses to defined ribosomal protein epitopes e

241 The functional heterogeneity of T cell responses to diverse antigens expressed at differ

242 l response, underlining the heterogeneity of T cell responses to HDM allergens.

243 g of the contribution of HIV-specific CD4(+) T cell responses to immune protection against HIV-1, par

244 ay influence context-specific macrophage and T cell responses to infection.

245 MDSC depletion may enhance T cell responses to lentiviral infection and the effecti

246 Further studies will determine whether T cell responses to neoepitopes are major disease driver

247 Moreover, IL-22 deficiency enhanced T cell responses to promote viral clearance, but increas

248 Our data demonstrate that T cell responses to rDENV2Delta30 are largely similar to

249 thway affects TG- and cornea-resident CD8(+) T cell responses to recurrent ocular herpesvirus infecti

250 tor (TCR) locus that was required for CD8(+) T cell responses to the Plasmodium berghei GAP5040-48 ep

251 CD8(+) T cell responses to these genome-wide epitopes were comp

252 Here we examined CD4 T cell responses to two leading TB vaccine antigens, ESA

253 sure proper programming of CD8(+) and CD4(+) T cell responses to viral infection.

254 T cell responses to viruses are initiated and maintained

255 We conclude that the T-cell response to brain metastases is not a surrogate o

256 The T-cell response to immunization was similar between geno

257 This study aimed to determine the T-cell response to Phl p 12 in profilin-sensitized patie

258 the cultured ELISPOT assay detected a higher T-cell response to pp65 than to IE-1 or IE-2, whereas in

259 No effect on antibody or T-cell response to tissue antigens in the Ltab-Ncr3 coul

260 cope of analysis to include in vitro-induced T-cell responses to 19 frequently recognized CMV protein

261 T-cell responses to commensals might support intestinal

262 T-cell responses to different gluten peptides appear to

263 y developed long-term, polyfunctional memory T-cell responses to Lassa virus.

264 r kappaB pathway, resulting in poor in vitro T-cell responses to mitogens and antigens caused by redu

265 help overcome immunosuppression and enhance T-cell responses to tumor antigens.

266 and MyD88 (CD8alpha:MyD88) to enhance CD8(+) T-cell responses to weakly immunogenic and poorly expres

267 We show this strategy elicits potent T cell responses toward highly conserved internal Ags wh

268 al pressure by joining innate and engineered T cell responses toward testing for sustained HIV remiss

269 lls play a pivotal role in restraining human T-cell responses toward environmental allergens and prot

270 strength, prevalence and cross-reactivity of T-cell responses towards Phl p 12 are comparable to the

271 important role as APC-expanding autoreactive T cell responses ultimately causing type 1 diabetes (T1D

272 Although IL-6 promoted virus-specific T cell responses, uncontrolled IL-6 expression in Ifitm3

273 106 epitopes accounted for half of the total T cell response, underlining the heterogeneity of T cell

274 e of immunotherapies that boost pre-existing T cell responses, understanding how different immune cel

275 the kinetics of viremia resolution, the CD8 T-cell response was of surprisingly high magnitude and p

276 t increase in HDV-specific CD4(+) and CD8(+) T-cell responses was evident when the third signal cytok

277 No increase in the magnitude of HCV-specific T-cell responses was observed at later time points, incl

278 To assess whether CCR2 directly regulates T cell responses, we followed the fates of CCR2(-/-) T c

279 k)/and IE(k)/SERCA2a 971-990 dextramers, the T cell responses were determined by flow cytometry to be

280 However, antibody and CD8(+) T cell responses were minimally affected.

281 FOXP3 + Treg cell numbers and tumor-specific T cell responses were observed, reaching similar levels

282 HPV-16-specific CD8(+) T cell responses were significantly induced and negative

283 Tumor-specific T cell responses were significantly lower in KT-CNI-SCC

284 decrease in FIX activity or capsid-specific T-cell responses were detected during transaminase eleva

285 erferon-positive (IFN-gamma(+)) Gag-specific T-cell responses were dominated by CD4(+) T cells (P < 0

286 Glycoprotein-specific T-cell responses were more frequent among those who rece

287 ralizing antibody (nAb) responses and CD8(+) T-cell responses were not significantly enhanced in the

288 Furthermore IFN-gamma-specific CD4(+) T-cell responses were reduced in immunocompromised pigs

289 -CMDR encoding subtype A Gagp55 Gag-specific T-cell responses were studied in 42 vaccinees using fres

290 ls studied, 13 made strong NK and gammadelta T cell responses, whereas 11 made feeble gammadelta T ce

291 ion had either a delayed or absent PD-1+ CD8 T-cell response, whereas 80% of patients with clinical b

292 on the antibody response than on the CD4(+) T cell response, which might influence the chosen strate

293 The patient with the more robust T-cell response, which was associated with a reduction i

294 Vaccine-elicited T-cell responses, which contribute to the control of HIV

295 se (ROCK)2 downregulates the proinflammatory T cell response while increasing the regulatory arm of t

296 iduals with Down syndrome can mount effector T-cell responses with similar phenotype and functionalit

297 e displayed markedly reduced Ag-specific CD4 T cell responses within the local draining iliac lymph n

298 ts with clinical benefit exhibited PD-1+ CD8 T-cell responses within 4 wk of treatment initiation.

299 both induced and maintained antitumor CD8(+) T-cell responses within directly treated tumors and prov

300 Control of HCV requires vigorous T-cell responses, yet CD4(+) T cells in chronic HCV pati